| Literature DB >> 16279764 |
Robert W Carling1, Andrew Madin, Alec Guiblin, Michael G N Russell, Kevin W Moore, Andrew Mitchinson, Bindi Sohal, Andrew Pike, Susan M Cook, Ian C Ragan, Ruth M McKernan, Kathleen Quirk, Pushpinder Ferris, George Marshall, Sally Ann Thompson, Keith A Wafford, Gerard R Dawson, John R Atack, Timothy Harrison, José L Castro, Leslie J Street.
Abstract
There is increasing evidence that compounds with selectivity for gamma-aminobutyric acid(A) (GABA(A)) alpha2- and/or alpha3-subtypes may retain the desirable anxiolytic activity of nonselective benzodiazepines but possess an improved side effect profile. Herein we describe a novel series of GABA(A) alpha2/alpha3 subtype-selective agonists leading to the identification of the development candidate 17, a nonsedating anxiolytic in preclinical animal assays.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16279764 DOI: 10.1021/jm058034a
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446